by admin | Jun 20, 2019 | news
These aren’t the typical slides you’d see at Endpoints — no molecules, clinical programs, or p-values. Instead, we’ll talk digital and internet trends, factors that elite global brands — regardless of industry — must first measure and understand before deploying...
by Viara Staneva | Jun 17, 2019 | news
Two new gene therapies—from Novartis and Spark Therapeutics—carry price tags higher than any other drugs in the U.S., elbowing aside the brands we’ve seen at the top for years, a GoodRx analysis shows. And with drugmakers doubling down in rare diseases, the...
by Viara Staneva | May 7, 2019 | news
Pharma hasn’t exactly won accolades for its speed in adopting new artificial intelligence and machine learning technologies. But while it’s drawn flak for that digital lag, it’s got good reason to proceed with caution where AI is concerned, one expert says. ...
by Viara Staneva | Apr 29, 2019 | news
Word came out just before the weekend (first at Endpoints) that GlaxoSmithKline is laying off R&D employees at both Stevenage (UK) and Upper Providence (US). Current leadership is re-organizing drug discovery efforts to put more emphasis on oncology,...
by Viara Staneva | Apr 25, 2019 | news
You need a license to cut-and-paste this copyrighted news content. Use this link to purchase your paid subscription ($200/year for individuals and $1,000/year for companies of every size): https://endpts.com/subscribeAlready a paid subscriber? Sign in to Endpoints...
by Viara Staneva | Apr 22, 2019 | news
CRISPR has been tested in US patients for the first time — but perhaps not in the manner you imagined. The University of Pennsylvania has led the way dosing two patients with relapsed cancers — one with multiple myeloma and one with sarcoma — with a T cell therapy in...
